We identify a novel dual-targeting c-Myc inhibitor D347-2761 targeting c-Myc unstable domain and c-Myc/Max heterodimerization, which further inhibits myeloma growth and infiltration in vitro and in vivo via regulating downstream CDK4 promoter transcriptional activity. This evidence concerns the gene MAX and plasma cell myeloma.